Bulletin
Investor Alert

New York Markets Close in:

April 5, 2021, 10:13 p.m. EDT

mRNA Vaccine and Therapeutics Market Size 2020 | Global Industry Report, Analysis, Growth, Trends and Forecast 2020-2025

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AstraZeneca PLC ADR (AZN)
  • X
    BioNTech SE ADR (BNTX)
  • X
    CRISPR Therapeutics AG (CRSP)

or Cancel Already have a watchlist? Log In

Apr 05, 2021 (SUPER MARKET RESEARCH via COMTEX) -- According to IMARC Group's latest report, titled " mRNA Vaccine and Therapeutics Market : Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025," the global mRNA vaccines and therapeutics market to witness moderate growth during the forecast period (2020-2025).

Request for a free sample copy of this report: https://www.imarcgroup.com/mrna-vaccines-therapeutics-market/requestsample

Market Trends

The messenger ribonucleic acid, or mRNA, refers to a protein-coding gene in the genome that provides a basis for protein synthesis within the cells. The mRNA vaccines and therapeutics include self-amplifying, in-vivo self-replicating, and in-vitro dendritic cell non-replicating mRNA that combine the desirable immunological properties. These vaccines are usually injected into the body to trigger virus-detecting immune sensors and produce viral antigen protein cells, which aid in enhancing the immunity of the body by improving B- and T- cell responses.

The mRNA vaccines are more effective against pathogens, cost-efficient, and have enhanced immunogenicity and higher potency. As a result, leading players are focusing on the development of an mRNA-based vaccine for the coronavirus disease (COVID-19). The success of the vaccine for COVID-19 can potentially boost the market growth. Along with this, improvements in healthcare technologies, such as the development of lipid nanoparticle formulations for in-vivo systemic delivery of mRNA, is providing a positive impact on the industry. Besides this, due to the increasing prevalence of chronic ailments, such as diabetes, tuberculosis, cancer and cardiovascular diseases (CVDs), pharmaceutical companies are investing to combine multiple molecules into single therapeutic medicines. Moreover, extensive research and development (R&D) activities in biotechnology and rapid advancements that have facilitated multiplexing of mRNA for improved product profiles, are expected to create a positive outlook for the market in the coming years.

mRNA Vaccines and Therapeutics Market 2020-2025 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

  • Argos Therapeutics Inc. (SCM Life Science and Genexine)

  • AstraZeneca /zigman2/quotes/200304487/composite AZN -0.51%

  • Bayer AG (otcmkts:BAYRY)

  • BioNTech AG /zigman2/quotes/214419716/composite BNTX -2.23%

  • Boehringer Ingelheim

  • CRISPR Therapeutics /zigman2/quotes/201181046/composite CRSP +3.00%

  • CureVac AG

  • eTheRNA Immunotherapies

  • Ethris GmbH

  • In-Cell-Art

  • Intellia Therapeutics Inc. /zigman2/quotes/207821052/composite NTLA +9.32%

  • Moderna Therapeutics /zigman2/quotes/205619834/composite MRNA +0.17%

  • Sangamo Therapeutics /zigman2/quotes/200395801/composite SGMO +5.02%

  • Tiba Biotech LLC

  • Translate Bio Inc. /zigman2/quotes/209811997/composite TBIO +0.44%

The report has segmented the market on the basis of vaccine type, treatment type, vaccine manufacturing, application, end-user and region.

Breakup by Vaccine Type:

  • Self-amplifying mRNA-based Vaccines

  • Conventional Non-Amplifying mRNA-Based Vaccines

  • Others

Breakup by Treatment Type:

  • Bioengineered Vaccine Based Treatment

  • Gene Therapy (Gene Silencing/Suppression)

  • Gene Transcription (Protein Generation)

  • Cell Therapy

  • Monoclonal Antibody Based Treatment

  • Others

/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 54.11
-0.28 -0.51%
Volume: 6.19M
May 11, 2021 3:00p
P/E Ratio
35.52
Dividend Yield
2.53%
Market Cap
$143.25 billion
Rev. per Employee
$365,423
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 197.84
-4.51 -2.23%
Volume: 4.05M
May 11, 2021 3:00p
P/E Ratio
1,895
Dividend Yield
N/A
Market Cap
$48.87 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/201181046/composite
US : U.S.: Nasdaq
$ 104.50
+3.04 +3.00%
Volume: 1.87M
May 11, 2021 3:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$7.69 billion
Rev. per Employee
$1,754
loading...
/zigman2/quotes/207821052/composite
US : U.S.: Nasdaq
$ 66.72
+5.69 +9.32%
Volume: 1.18M
May 11, 2021 3:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.16 billion
Rev. per Employee
$185,878
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 158.82
+0.27 +0.17%
Volume: 6.93M
May 11, 2021 3:00p
P/E Ratio
126.72
Dividend Yield
N/A
Market Cap
$63.45 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/200395801/composite
US : U.S.: Nasdaq
$ 10.68
+0.51 +5.02%
Volume: 1.01M
May 11, 2021 3:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.46 billion
Rev. per Employee
$286,179
loading...
/zigman2/quotes/209811997/composite
US : U.S.: Nasdaq
$ 18.08
+0.08 +0.44%
Volume: 1.07M
May 11, 2021 3:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.35 billion
Rev. per Employee
$1.14M
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.